Bortezomib

Proteasome inhibitor

Response rate
Single case report
Onset
Unknown
Route
SC or IV
Line
Investigational
IgM effect
Unknown

Evidence summary

Novel approach reported in 2024 in a patient without detectable serum IL-1β. Very preliminary.

Molecular targets (1)

MoleculeRoleExpressionEvidence
NF-κBMaster transcription factorPersistently activestrong

Sources (1)

J6Kanabaj K et al. (2024) Modern look at Schnitzler syndrome · ReumatologiaPubMed
Bortezomib for Schnitzler Syndrome | Kipine